Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
Document type:
Meeting Abstract
Author(s):
Chao, Joseph; Buxo, Elvira; Cervantes, Andres; Dayyani, Farshid; Rocha Lima, Caio Max Sao Pedro; Greil, Richard; Van Laarhoven, Hanneke W. M.; Lorenzen, Sylvie; Heinemann, Volker; Kischel, Roman; Shitara, Kohei; Lordick, Florian
Journal title abbreviation:
J Clin Oncol
Year:
2020
Journal volume:
38 Suppl S
Journal issue:
15
Print-ISSN:
0732-183X
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)